SCHEMBL7730860

SCHEMBL7730860

CC(C)(C)OC(=O)N1C[C@H](N(C(=O)CN)C(=O)OC(C)(C)C)C[C@H]1C=O

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
NR1H2 P55055 1/20 0.34
HSD11B1 P28845 2/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
AR P10275 1/20 0.31
HSD17B10 Q99714 1/20 0.30
CETP P11597 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8149676 1.00 NFKB1 (0.34) NFKB1NFKB2RELANR1H2HSD11B1
SCHEMBL7721935 0.83 NR1H2 (0.39) NFKB1NFKB2RELANR1H2HSD11B1
SCHEMBL7728185 0.83 HSD17B10 (0.34) NFKB1NFKB2RELANR1H2HSD11B1
SCHEMBL8150172 0.83 NR1H2 (0.39) NFKB1NFKB2RELANR1H2HSD11B1
SCHEMBL7727961 0.83 HSD17B10 (0.34) NFKB1NFKB2RELANR1H2HSD11B1
SCHEMBL7722122 0.83 NR1H2 (0.39) NFKB1NFKB2RELANR1H2HSD11B1
SCHEMBL7726101 0.83 HSD17B10 (0.34) NFKB1NFKB2RELANR1H2HSD11B1
SCHEMBL7726393 0.82 PTPN1 (0.39) NFKB1NFKB2RELANR1H2HSD11B1
SCHEMBL7733813 0.82 PTPN1 (0.39) NFKB1NFKB2RELANR1H2HSD11B1
SCHEMBL7733526 0.82 PTPN1 (0.39) NFKB1NFKB2RELANR1H2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 US disclosed